![Monica Bertagnolli’s statement about NIH’s plans to protect the integrity of NIH-supported research](https://oncodaily.com/pub/uploads/2024/08/1721743454057-e1723821012148.jpeg)
Monica Bertagnolli’s statement about NIH’s plans to protect the integrity of NIH-supported research
Monica Bertagnolli shared on LinkedIn:
“Over the past several years, NIH (National Institutes of Health), in coordination with other government agencies, has taken actions to address serious threats to the integrity of NIH-funded research. Most of the threats have originated from the People’s Republic of China.
We recognize that certain government actions to protect from these activities have had the unintended consequence of creating a difficult climate for our valued Asian American, Asian immigrant and Asian research colleagues. While I fully support NIH’s efforts to address serious integrity breaches instigated by the PRC, I believe there are opportunities to do this in a way that protects our relationships with our trusted Asian research colleagues.
Read more in my statement about NIH’s plans to protect the integrity of NIH-supported research while also encouraging scientific collaborations and cultivating a welcoming and supportive environment for Asian researchers.”
Source: Monica Bertagnolli/LinkedIn
Monica Bertagnolli is the Director of the National Institute of Health (NIH), USA. She is the President of Alliance for Clinical Trials In Oncology Foundation. She previously served as the Richard E. Wilson Professor of Surgery in the field of surgical oncology at Harvard Medical School, a surgeon at Brigham and Women’s Hospital, and a member of the Gastrointestinal Cancer Treatment and Sarcoma Centers at Dana-Farber Cancer Institute.
Dr. Bertagnolli is the Founding Chair of the minimal Common Oncology Data Elements (mCODE) executive committee and has held multiple positions nationally, including being Past President and Chair of the Board of Directors of the American Society of Clinical Oncology. In 2021, she was elected to the National Academy of Medicine, having previously served on the National Academies National Cancer Policy Forum.